Eversept Partners LP Has $8.73 Million Holdings in Palisade Bio, Inc. $PALI

Eversept Partners LP lessened its holdings in Palisade Bio, Inc. (NASDAQ:PALI) by 7.5% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,987,499 shares of the company’s stock after selling 404,049 shares during the quarter. Eversept Partners LP’s holdings in Palisade Bio were worth $8,728,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the business. XTX Topco Ltd increased its stake in Palisade Bio by 53.8% in the 4th quarter. XTX Topco Ltd now owns 21,669 shares of the company’s stock valued at $51,000 after buying an additional 7,584 shares during the last quarter. Cetera Investment Advisers bought a new stake in Palisade Bio during the 4th quarter worth about $25,000. Schonfeld Strategic Advisors LLC bought a new stake in Palisade Bio during the 4th quarter worth about $26,000. Virtu Financial LLC acquired a new position in shares of Palisade Bio during the 4th quarter worth about $28,000. Finally, Atom Investors LP acquired a new position in shares of Palisade Bio during the 4th quarter worth about $33,000. Institutional investors and hedge funds own 11.79% of the company’s stock.

Palisade Bio Stock Up 4.1%

Shares of NASDAQ PALI opened at $2.03 on Tuesday. The business’s 50 day moving average price is $1.93 and its two-hundred day moving average price is $1.90. The company has a market cap of $352.37 million, a PE ratio of -2.01 and a beta of 1.50. Palisade Bio, Inc. has a twelve month low of $0.53 and a twelve month high of $2.85.

Palisade Bio (NASDAQ:PALI) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). As a group, research analysts anticipate that Palisade Bio, Inc. will post -0.24 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and issued a $2.00 target price on shares of Palisade Bio in a research report on Tuesday, June 30th. Wall Street Zen raised Palisade Bio from a “sell” rating to a “hold” rating in a research report on Saturday. Wolfe Research started coverage on Palisade Bio in a research note on Thursday, April 9th. They issued an “outperform” rating and a $7.00 price target for the company. Weiss Ratings downgraded Palisade Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, July 14th. Finally, LADENBURG THALM/SH SH raised Palisade Bio to a “strong-buy” rating in a research report on Thursday, June 25th. Two research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $9.00.

Insider Buying and Selling

In related news, insider Mitchell Lawrence Jones sold 51,880 shares of the stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $2.05, for a total value of $106,354.00. Following the sale, the insider owned 94,009 shares in the company, valued at approximately $192,718.45. This represents a 35.56% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO John David Finley sold 146,798 shares of the firm’s stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $2.07, for a total value of $303,871.86. Following the sale, the chief executive officer directly owned 217,555 shares of the company’s stock, valued at $450,338.85. This represents a 40.29% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have acquired 125,000 shares of company stock valued at $250,100. 0.07% of the stock is owned by insiders.

Palisade Bio Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.